Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma

Next Previous
Trial Profile

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D

    • Most Recent Events

    • 19 Sep 2018 Results of a post-hoc analysis assessing patient reported outcomes in Reslizumab naive patients with historically elevated blood eosinophils (n=144) presented at the 28th Annual Congress of the European Respiratory Society
    • 06 Sep 2017 According to a Teva Pharmaceutical Industries media release, data from this trial will be presented at the 2017 European Respiratory Society (ERS) International Congress in Milan, Italy on September 9-13, 2017.
    • 18 Aug 2016 According to a Teva Pharmaceuticals media release, based on the data from this and other four trials (700193046, 700194103, 700194191 & 700212125) the European Commission has granted marketing authorization for reslizumab for the treatment of asthma.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top